Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Study Details
Study Description
Brief Summary
Study treatments:
-
Artemether-lumefantrine
-
Artesunate-amodiaquine
-
Dihydroartemisinin-piperaquine
Location:
Maradi, Niger
Principal Objective:
To measure the clinical and parasitological efficacy of the three artemisinin combination therapies over a period of 42 days from the start of treatment and with polymerase chain reaction assay (PCR) adjustment.
Secondary objectives:
-
To determine the blood concentration of the non-artemisinin component of the treatment (lumefantrine, desethylamodiaquine or piperaquine) at day 7
-
To assess the incidence of adverse events during the follow-up period;
-
To measure speed of parasite clearance
Methods:
In vivo non comparative study as for WHO standardised protocol. The study also measure the concentration of the non-artemisinin component.
Target population:
Children under 5 years of age consulting the integrated health centres of Andoumé and Dix-sept portes in Maradi.
Sample size:
221 patients per study treatment; 663 patients in total.
Treatment allocation:
Random.
Outcomes:
-
Early treatment failure,
-
Late clinical failure,
-
Late parasitological failure,
-
Adequate clinical and parasitological response.
Analysis:
-
Cumulative success or failure rate (Kaplan-Meier analysis).
-
Proportions of early treatment failures, late clinical failures, late parasitological failures, and adequate clinical and parasitological response (called also Per-protocol analysis).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Artesunate-amodiaquine Efficacy estimates at 95% |
Drug: Artesunate-amodiaquine
antimalarial ACT
Other Names:
|
| Other: Dihydroartemisinin-piperaquine Efficacy estimates at 95% |
Drug: Dihydroartemisinin-piperaquine
antimalarial ACT
Other Names:
|
| Other: Artemether-lumefantrine Efficacy estimates at 95% |
Drug: Artemether-lumefantrine
antimalarial ACT
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Adequate clinical and parasitological response [42 days after treatement start]
Absence of parasitaemia on day 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.
Secondary Outcome Measures
- Early treatment failure [1 to 3 days after tratment start]
General danger signs or signs of severe malaria on days 1, 2, or 3, in the presence of parasitaemia , or Parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature, or Parasitaemia on day 3 with axillary temperature ≥ 37.5°C, or Parasitaemia on day 3 ≥ 25% count on day 0 irrespective of axillary temperature.
- Late clinical failure [from day 4 to day 42 after treatment start]
General danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 42 in patients who did not previously meet any of the criteria of early treatment failure; or Presence of parasitaemia on any day between day 4 and day 42 with axillary temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure.
- Late Parasitological Failure [from day 7 to day 42 after treatment start]
- Presence of parasitaemia on any day between day 7 and day 42 with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age between 6 and 59 months
-
Weight ≥ 5 kg
-
Mono-infection with P. falciparum detected by microscopy
-
Parasitic density between 2,000 and 200,000 asexual forms /µL of blood
-
Axillary temperature ≥ 37.5°C or history of fever during the previous 24 hours
-
Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule (home is within one hour of walk from the outpatient department, no near-term travel plans, etc.)
-
Consent of a parent or guardian who is at least 18 years of age.
Exclusion Criteria:
-
Presence of general danger signs as defined by the WHO,
-
Presence of signs of severe malaria according to the definitions of WHO,
-
Severe anemia (haemoglobin <5 g/dL),
-
Known history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia,
-
Family history of sudden death or of congenital prolongation of corrected QT interval,
-
Use of antiarrhythmics or neuroleptics,
-
Known history of hypersensitivity to any of the study medications,
-
Severe malnutrition (defined as a weight-height ratio of < -3 z-score according to the 2006 WHO reference (20) and / or a mid-upper arm circumference lower than 115 mm and / or the presence of symmetrical oedema of the feet),
-
Presence of a febrile condition due to a disease other than malaria (i.e. measles, acute lower respiratory tract infection, otitis media, tonsillitis, abscess, severe diarrhoea with dehydration, etc.)
-
History of a full treatment course with one of the three study drugs in the past 28 days. The prior incomplete intake of one of the three study drugs or prior intake of antimalarial drugs not being tested in the study does not exclude a patient from participating in this study. However, information on these previous treatments will be carefully recorded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Andoumé Health Centre | Maradi | Niger |
Sponsors and Collaborators
- Epicentre
- Centre de Recherche Médicale et Sanitaire (Cermes), Niamey
Investigators
- Principal Investigator: Francesco Grandesso, MSc, Epicentre
- Study Chair: Lynda Woi Messe, MD, Epicentre
- Study Chair: Ibrahim M Laminou, PhD, Cermes
- Study Chair: Jean-François Etard, PhD, Epicentre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Epicentre/Nig/2012/Palu3ACT